This cluster groups 2 independently calculated changes: Capital expenditure increased 188.9%; Capex / revenue moved 3539 bp higher.
2 evidence-backed components· Pharmaceutical Preparations
RESEARCH SNAPSHOTWave Life Sciences, Inc.'s latest supported as-filed period reports revenue of $13.2M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Capital expenditure increased 188.9%; Capex / revenue moved 3539 bp higher.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Shares outstanding increased 23.8%; SBC / revenue moved 40118 bp higher.
2 evidence-backed componentsCurrent assets changed +127.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
WVE · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-432714SEC ↗8-KOct 27, 2026Period Oct 27, 20260001193125-26-432690SEC ↗4Oct 7, 2026Period Oct 5, 20260001231919-26-001433SEC ↗4Oct 7, 2026Period Oct 5, 20260001193125-26-417237SEC ↗4Oct 7, 2026Period Oct 5, 20260001193125-26-417236SEC ↗4Oct 7, 2026Period Oct 5, 20260001193125-26-417234SEC ↗4Oct 7, 2026Period Oct 5, 20260001193125-26-417233SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Oct 5, 2026Filed Oct 7, 2026 | Verdine Gregory L.Director | Grant Or AwardDirect | 10,700 | $0 | $0 | Form 4 ↗ |
| Oct 5, 2026Filed Oct 7, 2026 | Verdine Gregory L.Director | Grant Or AwardDirect | 64,000 | $0 | $0 | Form 4 ↗ |
| Oct 5, 2026Filed Oct 7, 2026 | RA CAPITAL MANAGEMENT, L.P.Director | Grant Or AwardIndirect | 10,700 | $0 | $0 | Form 4 ↗ |
| Oct 5, 2026Filed Oct 7, 2026 | RA CAPITAL MANAGEMENT, L.P.Director | Grant Or AwardIndirect | 64,000 | $0 | $0 | Form 4 ↗ |
| Aug 11, 2026Filed Aug 13, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Total assets changed +121.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current ratio changed +290.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Free-cash-flow proxy changed -33.9% from the comparable as-filed period.
Operating income changed -39.9% from the comparable as-filed period.
Operating cash flow changed -34.6% from the comparable as-filed period.
Current assets changed +112.8% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-09-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-417232| Wagner Heidi LDirector |
| Open Market SaleDirect |
| 7,000 |
| $6 |
| $42,070 |
| Form 4 ↗ |
| Aug 11, 2026Filed Aug 13, 2026 | Wagner Heidi LDirector | Option ExerciseDirect | 7,000 | $0 | $0 | Form 4 ↗ |
| Aug 11, 2026Filed Aug 13, 2026 | Wagner Heidi LDirector | Option ExerciseDirect | 7,000 | $6 | $41,790 | Form 4 ↗ |